Journals / Türk Toraks Dergisi / 2010 / Cilt: 11 - Sayı: 1

The value of diagnostic procedures and the mortality in malignant mesothelioma cases

Malign plevral mezotelyoma olgularında tanısal işlemlerin değeri ve mortalite

Pages
26–29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Immunohistochemical staining should be perfomed for differentiating subtypes.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this study, our aim was to evaluate the general characteristics of the malignant pleural mesethelioma (MPM) cases, value of interventions used for diagnosis and to define the mortality of cases.
📊
Key Findings & Data:Records of the Population Registry Office of Tokat were used to determine the median survival rate and mortaliy at 6, 12, 24 and 48 months.
💡
Conclusion & Impact:Immunohistochemical staining should be perfomed for differentiating subtypes.
🔬Design:Research Article
📍Scope:24 samples
⚙️Variables:Domain Parameters

Abstract

Objective: In this study, our aim was to evaluate the general characteristics of the malignant pleural mesethelioma (MPM) cases, value of interventions used for diagnosis and to define the mortality of cases. Material and Method: Records of patients were evaluated retrospectively. Records of the Population Registry Office of Tokat were used to determine the median survival rate and mortaliy at 6, 12, 24 and 48 months. Results: Thirty five MPM patients were included in the study. The mean age was 61.5 years, and 17 of them were males. The most common complaint was dyspnea (86%), 24 of them had a history of environmental asbestos exposure. The value of diagnostic interventions was analyzed by the data of 27 patients who were diagnosed in our hospital. The cytology of pleural effusion was diagnostic in 7 of 24 samples (29%), and closed pleural biopsy in 10 of 22 samples (46%). Thoracoscopic biopsy was performed in 13 patients and and excisional biopsy from the chest wall in one patient, and all were diagnostic. Eight of 27 patients were diagnosed as epithelial type MPM, 17 patients (63%) could not be classified. All of the 13 patients whose samples were stained immunohistochemically showed strong / intermediate positivity for calretinin. Immunohistochemical staining was not useful in differentiating subtypes in 5 patients. Median survival was 14.9 months for all patients. Three patients (8.6%) died in the first six months. The mortalities for 12, 24 and 48 months were 42%, 65%and 100%, respectively. Conclusion: MPM should be considered in cases who had a history of asbestos exposure. Immunohistochemical staining should be perfomed for differentiating subtypes.

Özet

Amaç: Bu çalışmada amacımız malign plevra mezotelyoma (MPM) olgularının genel özelliklerini; tanısal işlemlerin verimliliklerini değerlendirmek ve mortaliteyi belirlemekti. Gereç ve Yöntem: Olguların dosyaları incelendi. İl Nüfus Müdürlüğü kayıtları kullanılarak 6.ayda, 1., 2. ve 4. yıldaki ölüm oranları ve ortalama yaşam süreleri hesaplandı. Bulgular: Otuz beş MPM olgusu çalışmaya alındı. Yaş ortalaması 61.5 idi ve 17'si erkekti. En sık başvuru yakınması nefes darlığı (%86) idi ve 24 olgunun çevresel asbest maruziyeti vardı. Tanısal uygulamaların sonuçları ile ilgili değerlendirme hastanemizde tanı konulan 27 olgunun verilerine dayanarak yapıldı. Plevra sıvı sitolojisi 24 olgunun 7'sinde (%29), kapalı plevra biyopsisi 22 olgunun 10'unda (%46) tanısaldı. 13 olgudan torakoskopik plevra biyopsisi ve 1 olgudan göğüs duvarında palpe edilen kitleden eksizyonel biyopsi alınmıştı ve tüm örnekler tanısaldı. Yirmi yedi olgunun 8'inde tümör epitelial tipte idi, 17 olguda (%63.0) subtip ayrımı yapılamamıştı. Kalretinin ile immunhistokimyasal (İHK) boyama yapılan 13 olgunun hepsinde kuvvetli/orta şiddette sitoplazmik boyanma saptanmıştı. İHK boyama ile 5 olguda (%35.7) suptip ayrımı yapılamamıştı. Tüm olguların ortalama yaşam süresi 14.9 aydı. 3 olgu (%8.6) ilk 6 ayda ölümle sonuçlanmıştı. 1., 2. ve 4. yıl mortaliteleri sırasıyla %41.7, %64.7 ve %100.0 idi. Sonuç: Asbest maruziyetinin yaygın olduğu bölgelerden gelen olgularda MPM düşünülmeli, tanıda subtip ayrımı için İHK boyama kullanılmalıdır.

🔖

Cite This Article

DORUK, S., KÖSEOĞLU, D. R., YEĞİNSU, A., İNÖNÜ, H., YILMAZ, A., ÇELİKEL, S., SEYFİKLİ, Z. (2010). The value of diagnostic procedures and the mortality in malignant mesothelioma cases. Türk Toraks Dergisi, Cilt: 11 - Sayı: 1, 26–29. https://ajindex.com/articles/329567

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (19)

  1. Gibbons W. The exploitation and environmental legacy of amphibole asbestos: a late 20th century overview. Environmental Geochemistry and Health 1998;20:213-30
  2. World Health Organization. Elimination of Asbestos-Related Diseases. Geneva. http:// www.who.int/occupational health/publications/asbestosrelated diseases. Güncelleme 2006, Son erişim 01.06.2009
  3. Montanaro F, Rosato R, Gangemi M, et al. Survival of pleural malignant mesothelioma in Italy: A population-based study. Int J Cancer 2009;124:201-7
  4. Örki A, Keleş M, Ürek Ş, ve ark. Malign plevral mezotelyomada kombine (multimodalite) tedavi. İzmir Göğüs Hastanesi Dergisi 2003;17:19-28
  5. Metintaş M. Primer plevra maligniteleri. Solunum 2002;4:149-64
  6. Zervos MD, Bizekis C, Pass HI. Malignant mesothelioma 2008. Curr Opin Pulm Med 2008;14:303-9
  7. Metintas M, Hillerdal G, Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J 1999;13:523-26
  8. Özvaran MK. Malign mezotelyomada gen tedavisi. Toraks. Dergisi 2004;5:110-5
  9. Bruce WS. Robinson, A. Philippe Chahinian, eds. Mesothelioma. London, Martin Dunitz Ltd, 2002
  10. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the north western cape province. Br J Ind Med 1960;17:260 71
  11. Dikensoy O. Mesothelioma due to environmental exposure to erionite in Turkey. Curr Opin Pulm Med 2008;14:322-5
  12. Metintas M, Ozdemir N, Hillerdal G. Environmental asbestos exposure and malignant pleural mesothelioma. Respir Med 1999;93:349-55
  13. Şenyiğit A, Coşkunsel M, Topçu F, ve ark. Malign plevral mezotelyoma: 136 olgunun klinik radyolojik ve histolojik değerlendirilmesi. Tub Toraks 2000;48:26-34 (Özet
  14. Witherby SM, Butnor KJ, Grunberg SM. Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer 2007;57:410-3 (özet)
  15. TC. Sağlık Bakanlığı Kanser Savaş Daire Başkanlığı. Ulusal Mezetelyoma Kurulu, http://www.mesothelioma-tr.org/ Son erişim 01.06.2009
  16. Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol 1997;145:211-8
  17. Moore AJ, Parker R, Wiggins J. Malignant mesothelioma. Orphanet J Rare Dis 2008;19:3:34
  18. Selçuk ZT, Cöplü L, Emri S, et all. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest 1992;102:790-6
  19. Yates DH, Corrin B, Stidolph PN, et all. Malignant mesothelioma in south east England: c